KNSA logo

KNSA Kiniksa Pharmaceuticals International, plc

NASDAQ · Medical - Pharmaceuticals · Healthcare

$94.23
-2.10 (-2.18%)

Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-38…

Market Cap: $7.40Bwww.kiniksa.com

Price

No data yet.

Social Signal Score

58
5d
65
1 mentions
—
30d
57
7 mentions
—
60d
57
7 mentions
—
90d
55
9 mentions
—
news: 9

Analyst Ratings

11 analysts
Buyconsensus
Strong Buy 0Buy 11Hold 0Sell 0Strong Sell 0
Avg price target$93-1.3%
Low $74Median $98.5High $101
Current Consensus

Revenue

$285.97M
$0.00$95.32M$190.65M$285.97M
Mar 2017Sep 2026

Analyst Estimates

FY2025
$0.97
$0.84–$1.11
4 analysts
FY2026
$1.48+52% YoY
$1.43–$1.52
4 analysts
FY2027
$2.03+36% YoY
$1.57–$2.63
4 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Sanj K. Patel
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Employees
366
Beta
0.08
Country
GB
Piotroski score
6 / 9 (Middling)
Altman Z-score
17.87
www.kiniksa.com